Antialergico

Quick links to important sections

Antialergico

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Antialergico

Quick Facts

Property Description
Active Ingredient Synthetic H1-receptor antagonist (e.g., Cetirizine)
Form Tablets, Oral solutions, Nasal sprays
Pharmacological Class Second-generation H1-receptor Antagonist
Common Use Relief of general allergic symptoms
Origin Synthetic chemical compound

What Type of Medicine is Antialergico?

The term Antialergico refers to a branded or general medication whose active component is a highly selective second-generation H1-receptor antagonist, a specific class of synthetic chemical compound. This pharmacological classification is verified across major pharmacopeias and is primarily used to provide symptomatic relief from various allergic manifestations in the general population. Unlike first-generation antihistamines, this agent is structurally designed to minimize passage across the blood-brain barrier, which is its primary differentiating factor from older counterparts.

Composition, Origin, and Differentiation

The core composition of Antialergico centers on its synthetic chemical compound active ingredient, which is available for both systemic treatment (via oral ingestion in tablets or oral solutions) and topical application (in nasal spray solutions or eye drops). This compound is often positioned for patients requiring continuous daily management of common discomforts, such as allergic rhinitis, without the drowsiness associated with first-generation agents. It is widely available for purchase over-the-counter (OTC), reflecting its established safety profile for broad patient access.

Mechanism and Relief

The relief provided by Antialergico stems from its ability to interrupt the allergic chemical cascade through competitive antagonism. The active ingredient occupies the H1 receptor sites on cells, thereby preventing the naturally released inflammatory chemical, histamine, from binding and triggering allergic symptoms. This action is crucial for suppressing manifestations like pruritus (itching), rhinorrhea, and localized edema, and is a mechanism for effectively managing the physical effects of an allergic response.

What side effects are possible with Antialergico?

Possible Side Effects and Safety Information

The official safety profile for Antialergico (a second-generation H1-receptor antagonist) is formally defined by government regulatory agencies, classifying adverse reactions by frequency and affected physiological system. The most frequently documented adverse effects fall into the Common category, while serious reactions are classified as Rare or Very Rare.


Frequency-Classified Adverse Reactions

Adverse reactions are grouped according to the estimated incidence reported in regulatory documents:

Frequency Classification Examples of Documented Effects
Common (ge 1/100) Somnolence, Headache, Fatigue, Dry mouth, Nausea, Pharyngitis.
Uncommon (ge 1/1,000) Paresthesia (abnormal skin sensation), Agitation, Pruritus, Rash.
Rare (ge 1/10,000) Hypersensitivity, Convulsions, Tachycardia, Oedema, Abnormal hepatic function.
Very Rare (<1/10,000) Anaphylactic shock, Syncope, Dyskinesia, Dystonia.
Not Known Suicidal ideation, Urinary retention, Aggression.

Official Safety Considerations

The regulatory labeling addresses specific safety contexts. Serious adverse reactions officially listed include Anaphylactic Shock, Convulsions, and Abnormal Hepatic Function. These effects are classified as Rare or Very Rare. Adverse reactions are grouped across multiple System-Organ Classes, including Nervous System, Gastrointestinal, Psychiatric, and Renal/Urinary systems.

Safety constraints are defined for certain patient populations and co-use scenarios. Dose adjustment is required for patients with Renal Impairment due to altered drug clearance. Caution is advised for patients with predisposing factors for Urinary Retention. Furthermore, concomitant use with alcohol or other central nervous system (CNS) depressants may cause an additive reduction in alertness. The regulatory documents also note that Pruritus (itching) upon stopping treatment is a potential time-related adverse pattern.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Antialergico overdose centers on the rapid assessment of neurological and cardiac status. Documented clinical manifestations of overdose commonly include central nervous system (CNS) depression, presenting as somnolence, drowsiness, sedation, and fatigue, alongside mild gastrointestinal effects such as diarrhea.

Immediate medical attention or contacting a poison control center is explicitly mandated due to the potential for severe systemic outcomes. Regulatory documents list the risk of pronounced CNS depression escalating to convulsions or coma, and the presence of tachycardia as serious manifestations.

Management is defined as symptomatic and supportive treatment, with the official documentation confirming that no specific antidote is known. Close observation and, if severe symptoms are present, continuous cardiac monitoring may be required. Population-specific regulatory notes indicate that pediatric patients may show paradoxical restlessness or irritability, while geriatric patients often exhibit increased sensitivity to CNS effects. Hemodialysis is officially noted as ineffective for clearance.

Therapeutic Uses of Antialergico

What Antialergico Treats: Main Uses and Benefits

Antialergico is commonly used to provide symptomatic support across typical manifestations of allergic disease, particularly conditions where symptoms may intensify temporarily. This class of medicine is relevant in contexts involving heightened systemic burden. It helps address symptom clusters that interfere with daily comfort, relevant for both seasonal and perennial Allergic Rhinitis, as well as Chronic Idiopathic Urticaria (hives).

Quick Fact: Symptomatic Support for Pruritus

Therapeutic Domain Conditions & Manifestations Primary Benefit
Allergology Allergic Rhinitis, Chronic Idiopathic Urticaria Assists with maintaining functional stability
Symptom Focus Rhinorrhea, Sneezing, Ocular Pruritus, Skin Welts Helps ease the overall symptom load

Supportive Management for Allergic Symptoms

The medication is generally considered relevant for easing rhinorrhea (runny nose), sneezing, ocular pruritus (itchy eyes), and the pruritus and raised welts associated with skin reactions. Applied in scenarios requiring additional management of discomfort, it helps ease the overall symptom load during periods of heightened symptoms. This supportive benefit assists with maintaining functional stability, offering relief for patients requiring continuous daily management.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility Status

Population Group Regulatory Status Primary Constraint
Absolute Contraindication Must Not Use Hypersensitivity to the active substance (Cetirizine), Hydroxyzine, or any piperazine derivatives; Severe Renal Impairment (Creatinine Clearance leq 10 mL/min).
Restricted Use Conditional Use Moderate Renal or Hepatic Impairment: Requires a formal reduction of the approved dose due to decreased clearance. Older Adults (65 years): Caution is required, often necessitating a lower starting dose due to diminished renal function.
Pregnancy/Lactation Conditional Use Pregnancy: No adequate studies exist; use only if clearly needed. Lactation: Generally not recommended due to excretion into breast milk.

The medicine is officially authorized for use in Adults and Adolescents (12 years). Specific pediatric use is established for children mathbfgeq 6 months of age for chronic hives and year-round allergies, and mathbfgeq 2 years of age for seasonal allergies. Safety and effectiveness are not established for infants under 6 months. Furthermore, caution is required for patients with a predisposition to urinary retention or known epilepsy, as stated in the prescribing information.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Antialergico is defined by two primary regulatory domains: pharmacodynamic reinforcement and pharmacokinetic modification. These domains strictly detail the interacting substances and resulting mechanistic outcomes documented in official government sources.

Formal Restrictions and Pharmacodynamic Effects

Co-administration is formally restricted with medicines derived from piperazine, including Hydroxyzine, due to the structural relationship of the compounds. The concurrent use of Antialergico with alcohol or other CNS depressants (such as certain antianxiety medications and opioid pain relievers) may result in an officially documented additive pharmacodynamic effect, leading to additional reductions in alertness and impaired performance. While a formal study found no significant change in drug exposure at a specific blood alcohol level, the caution regarding additive CNS effects remains.

Pharmacokinetic and Exposure Modification

Regulatory documents state that co-administration with Theophylline (at a 400 mg once-daily dose) resulted in a 16% decrease in Antialergico clearance. Antialergico is also documented as a P-glycoprotein (P-gp) substrate. Consequently, co-administration with P-gp inhibitors may increase the plasma level or effect of Antialergico. Regarding dietary intake, the presence of food delays the rate of absorption, meaning the time to reach peak concentration (Tmax) is prolonged, though the total amount of the drug absorbed is not affected. Furthermore, patients with documented hepatic and/or renal impairment may experience reduced drug clearance and an increased half-life, which impacts interaction considerations.

Mechanism of Action

How Antialergico Works

Selective Blockade of Peripheral H1 Receptors

This second-generation agent acts as a competitive antagonist, binding with high affinity to the Histamine-1 ( H1) receptor located primarily on cells outside the central nervous system. This molecular action interrupts the signaling sequence initiated by released histamine, which is the body's primary acute inflammatory mediator.

Regulation of Vascular and Endothelial Response

The mechanism is applied to systems where histamine activity causes excessive signaling. By preventing histamine binding, the drug facilitates the regulation of vascular permeability, inhibiting the process where endothelial cells contract and allow plasma fluid to leak into tissues. This physiological action results in reduced plasma fluid exudation.

Suppression of Sensory Nerve Excitation and CNS Selectivity

The molecule engages mechanisms that regulate overactive sensory input by blocking H1 receptors on peripheral nerve endings, which transmit the signals of sensory irritation. Crucially, the molecule's structural design limits its ability to cross the blood-brain barrier, maintaining minimal activity on central H1 receptor pathways.

Dosage and Administration Information

How to use Antialergico

The administration of Antialergico is structured by standard practices, specifying both the oral route for routine use and the intravenous (IV) route for the treatment of acute urticaria in supervised settings. The primary oral dosage for adults and adolescents is 10 mg administered once daily. A 5 mg dose once daily may also be utilized, but the maximum daily dose should not exceed 10 mg in a 24-hour period. Oral tablets may be swallowed whole with liquid and can be taken with or without food, as meal consumption does not significantly alter the overall drug absorption.

The standard frequency for maintenance use is once daily. For the IV formulation, 10 mg is administered as an intravenous push over 1 to 2 minutes, with repetition limited to once every 24 hours as needed for acute symptoms. Dosing must be adjusted for patients with impaired renal function, reflecting the drug's primary elimination pathway. For moderate renal impairment, the dose is typically reduced to 5 mg once daily, and for severe impairment, it may be reduced further to 5 mg once every two days. No dose reduction is typically necessary for older adults with normal renal function. Patients requiring allergy skin tests must observe a procedural wash-out period of 3 days after stopping repeated administration to avoid inhibition of test results.

Recent Clinical Evidence

Recent Clinical Evidence: Antialergico


Clinical research consistently supports second-generation H1-antihistamines as the first-line pharmacologic treatment for conditions like allergic rhinitis (hay fever) and chronic spontaneous urticaria (hives). These newer agents, such as cetirizine, fexofenadine, and loratadine, are preferred over first-generation sedating antihistamines (e.g., diphenhydramine) due to their improved safety profile, faster onset of action, and significantly lower risk of sedation or cognitive impairment. Studies have demonstrated that second-generation antihistamines are equally or more effective than their older counterparts in relieving symptoms of allergic rhino-conjunctivitis and urticaria.

Efficacy and Safety Comparison

High-quality clinical trials affirm that first-generation antihistamines readily cross the blood-brain barrier, leading to central nervous system effects such as drowsiness and impaired performance. In contrast, second-generation agents are more selective for peripheral H1-receptors, resulting in a minimal to non-sedating effect at recommended doses. This distinction is critical, particularly for patients who need to remain alert for driving or operating machinery.

Antihistamine Generation Key Difference Clinical Implications
First-Generation Easily crosses the blood-brain barrier. High risk of sedation; impaired coordination.
Second-Generation Primarily targets peripheral H1-receptors. Minimal to no sedation; improved safety for daily activities.

Role in Refractory Urticaria

For patients with chronic spontaneous urticaria that does not respond adequately to standard doses of second-generation H1-antihistamines, clinical guidelines often recommend increasing the antihistamine dosage up to four times the standard dose, a practice supported by evidence. Furthermore, when antihistamines alone are insufficient, antileukotriene agents (such as montelukast) are sometimes used as an add-on therapy. Systematic reviews and meta-analyses suggest that combining a leukotriene receptor antagonist with H1-antihistamines can modestly improve symptoms and quality of life for individuals with refractory urticaria, with no significant increase in overall adverse events.

Frequently Asked Questions (FAQ)

Common questions about Antialergico (FAQ)


Q: How long does it typically take for Antialergico to start working?

A: Official clinical studies indicate that the medication begins to interrupt the allergic response rapidly. Research shows that the inhibition of histamine-induced skin reactions began within 20 minutes for 50% of the study subjects and within one hour for 95% of subjects after administration.


Q: Is feeling nervous or irritable a known general side effect of Antialergico?

A: Official safety data lists 'Agitation' as an uncommon side effect and 'Nervousness' as a reported symptom. These reactions are described as generally associated with the minimal central nervous system (CNS) effects that can be observed with antihistamines.


Q: Are there any reported side effects of Antialergico on vision?

A: Reported adverse reactions have included visual disturbances and accommodation disorder (difficulty focusing). According to official product information, these effects are generally classified as rare or very rare events.


Q: Is it possible for Antialergico to interact with vitamins or herbal supplements?

A: The official label specifies interactions with certain prescription medicines and alcohol. While most common vitamins and herbs are not explicitly listed, regulatory advice notes that the concurrent use of the drug with supplements that may cause drowsiness could lead to additive effects.


Q: Does Antialergico interact with commonly prescribed blood pressure medications?

A: No significant interactions are typically cited for the single-ingredient Antialergico product. However, official documents describe high blood pressure as a precaution when using combination products that include a decongestant, as the condition may be worsened by the decongestant component.


Q: Is there an interaction between Antialergico and common sleep aids?

A: Regulatory documents describe a known interaction between Antialergico and central nervous system (CNS) depressants, which includes many common sleep aids. Co-administration may result in an additive pharmacodynamic effect, leading to an increased reduction in alertness and potentially impaired performance.


Q: What is the official information regarding Antialergico use during pregnancy?

A: Official information states that adequate and well-controlled studies in pregnant women are currently lacking. Regulatory documents indicate that the medication is considered for use during pregnancy only if it is clearly needed, with a risk-benefit assessment by a healthcare professional.


Q: Is Antialergico safe to use while breastfeeding, according to official sources?

A: Regulatory documents indicate that the active ingredient in Antialergico is excreted into human breast milk. Due to the potential for adverse effects on the nursing infant, official information suggests that its use should generally be avoided while breastfeeding.


Q: What is the recommended period for continuous use of Antialergico?

A: Antialergico is intended for both acute and chronic use, and its regulatory status means there is no formal maximum duration of use. When considering daily use for an extended period (such as a few months or more), official guidance emphasizes that the benefits and risks of long-term use should be reviewed with a healthcare professional.


Q: What is the general information about taking Antialergico at a specific time of day?

A: The product is generally administered once daily. Because somnolence (drowsiness) is listed as a common side effect in official safety documents, it is noted that some people may prefer to take the dose in the evening, which may help minimize potential impact on daytime alertness.


Q: Is Antialergico a fast-acting allergy medicine?

A: Official regulatory data indicates that the onset of antihistaminic activity for Antialergico is prompt. Clinical studies show that the inhibition of allergic responses begins, with the onset starting within 20 minutes for a majority of study subjects.


Q: Why do some sources suggest taking Antialergico at night?

A: The suggestion to administer Antialergico in the evening is primarily related to its known side effect profile. Somnolence (drowsiness) is listed as a common adverse reaction in official safety documents, and taking the single dose at night may help manage this effect.


Q: Can Antialergico be used for non-allergic symptoms like common cold symptoms?

A: According to the official regulatory indications, Antialergico is used only for the relief of symptoms due to allergic rhinitis (hay fever) and chronic idiopathic urticaria (hives). It is not indicated for treating the non-allergic symptoms typically associated with the common cold.


Q: How does the active ingredient in Antialergico differ from that in other over-the-counter options?

A: Antialergico is classified as a second-generation H1-receptor antagonist. This means its active ingredient is chemically designed to minimally cross the blood-brain barrier. This structural feature differentiates it from older, first-generation antihistamines, which carry a greater risk of sedation.


Q: How long has Antialergico been approved for general use by regulatory bodies?

A: While the specific brand approval dates vary internationally, the active ingredient that defines Antialergico as a second-generation antihistamine has been approved and widely available since the 1990s. Its regulatory history demonstrates its established use for managing allergic conditions.


Q: What kind of research studies have been conducted on Antialergico's efficacy?

A: The efficacy of Antialergico has been formally studied in placebo-controlled, double-blind clinical trials. These studies, which have involved both adults and children, provided the evidence base for its use in treating conditions like seasonal allergic rhinitis and chronic idiopathic urticaria.


Q: Is there evidence about the safety profile of the long-term use of Antialergico?

A: Regulatory agencies have issued safety communications regarding a specific adverse pattern related to long-term use. This information addresses the rare risk of experiencing severe itching, known as pruritus, which has been reported after stopping the medication following months of daily administration.


Q: What happens if a person misses taking a dose of Antialergico?

A: General guidance regarding a once-daily medication suggests that if a dose is missed, it can be administered as soon as it is remembered. However, if it is already near the time for the next scheduled dose, regulatory guidance indicates that the missed dose is usually omitted. Doses should not be doubled.


Q: What should a person do if their allergy symptoms do not improve while taking Antialergico?

A: Official guidelines state that if symptoms persist or worsen, the use of the product should be stopped. Specifically, if hives do not improve within three days or last longer than six weeks, patients are advised to seek guidance from a healthcare professional.


Q: Does Antialergico contain a decongestant like pseudoephedrine?

A: The single-ingredient product Antialergico does not contain any decongestant, such as pseudoephedrine. Combination products containing both the antihistamine and a decongestant component are manufactured and made available separately.


Q: Has Antialergico ever had a major regulatory safety warning or update?

A: Yes, regulatory agencies recently issued a safety communication regarding a new and specific update. This information addressed the rare risk of severe itching (pruritus) that has been reported after individuals discontinued the long-term, daily administration of the medication.


Q: Why might a doctor suggest switching from Antialergico to a different medication?

A: Regulatory guidance and clinical evidence suggest that if a condition, such as chronic urticaria, does not show an adequate response, professionals may consider changes to the patient's regimen. Evidence indicates this approach may involve dose optimization or utilizing an alternative agent.

How should Antialergico be stored and disposed of?

How to Store and Dispose of Antialergico?

This medication must be stored according to official regulatory specifications to maintain its stability and effectiveness.

Storage Requirements

Condition Specification
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Keep protected from excessive heat and moisture. Do not freeze liquid formulations.
Container Keep in the original container with the lid tightly closed.

Child Safety and Disposal

Store the medicine out of the sight and reach of children to prevent accidental ingestion. Dispose of expired or unused product following local regulations and established drug take-back programs. If no take-back program is available, mix the product with an unappealing substance, place it in a sealed bag, and discard it in the household trash. Do not flush down a toilet unless specified on the labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Antialergico found in:

A-Z Index: